NCT04938375 (SeLeBêta) is a clinical trial in Cardiogenic Shock, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT04938375?

NCT04938375 is sponsored by Central Hospital, Nancy, France.

What condition does NCT04938375 study?

NCT04938375 studies Cardiogenic Shock, Arrythmia.

Is NCT04938375 still recruiting?

NCT04938375 is currently status unknown. Last updated 24 June 2021.

Last reviewed 2021-06-24 · How we verify

NCT04938375: SeLeBêta

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Profile of the Combination of Levosimendan and IV Beta Blocker in Cardiogenic Shock: a Retrospective Study

Status unknown Last updated 24 June 2021

What this trial tests

trial in Cardiogenic Shock in 25 participants. Status unknown.

Timeline

1 January 2016

Primary endpoint
30 June 2021

30 July 2021

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	25
Start date	1 January 2016
Primary completion	30 June 2021
Estimated completion	30 July 2021

Conditions studied

Cardiogenic Shock — all drugs for Cardiogenic Shock →
Arrythmia — all drugs for Arrythmia →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Cardiogenic Shock or Arrythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety profile of the combination of Levosimendan and beta blocker in cardiogenic shock with arrythmia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiogenic Shock

Currently open trials in the same condition.

NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04938375 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 24 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04938375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing